Article
Comparative study of Parkinson's disease and leucine-rich repeat kinase 2 p.G2019S parkinsonism.
Neurobiology of aging - 1 May 2014
Trinh Joanne, Amouri Rim, Duda John E, Morley James F, Read Matthew, Donald Alan, Vilariño-Güell Carles, Thompson Christina, Szu Tu Chelsea, Gustavsson Emil K, Ben Sassi Samia, Hentati Emna, Zouari Mourad, Farhat Emna, Nabli Fatma, Hentati Faycel, Farrer Matthew J
Abstract excerpt
Parkinson disease is a progressive neurodegenerative disease for which leucine-rich repeat kinase 2 (LRRK2 carriers) p.G2019S confers substantial genotypic and population attributable risk. With informed consent, we have recruited clinical data from 778 patients from Tunisia (of which 266 have LR...
Topics
- Age Factors
- Age of Onset
- Aged
- Case-Control Studies
- Cognition
- Disease Progression
- Female
- Humans
- Incidence
- Leucine-Rich Repeat Serine-Threonine Protein Kinase-2
- Male
- Middle Aged
- Molecular Targeted Therapy
